全景望远镜
硼替佐米
地塞米松
多发性骨髓瘤
医学
肿瘤科
内科学
Carfilzomib公司
生物
生物化学
组蛋白
基因
组蛋白脱乙酰基酶
作者
Paul G. Richardson,Vânia Hungria,Sung‐Soo Yoon,Meral Beksaç,Meletios Α. Dimopoulos,Ashraf Elghandour,W Wiktor-Jędrzejczak,Andreas Guenther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Robert Schlossman,Jian Hou,Philippe Moreau,Sagar Lonial,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Bourras‐Rezki Bengoudifa,Claudia Corrado,Florence Binlich
出处
期刊:Blood
[Elsevier BV]
日期:2015-12-02
卷期号:127 (6): 713-721
被引量:130
标识
DOI:10.1182/blood-2015-09-665018
摘要
Key Points Benefit from panobinostat-dexamethasone-bortezomib was greatest in patients who received ≥2 prior regimens including bortezomib and IMiDs.
科研通智能强力驱动
Strongly Powered by AbleSci AI